Drug-induced inflammatory bowel disease (IBD) is a clinical entity on the rise due to the frequent use of immunomodulatory therapy. Here we report the case of Crohn's disease due to Ocrelizumab, a humanized anti-CD20 monoclonal antibody approved for the treatment of multiple sclerosis. The exact mechanism by which anti-CD20 antibodies can trigger IBD is unknown, but since IBD and multiple sclerosis are processes included within the spectrum of immunomediated diseases, we could suggest that Ocrelizumab could trigger IBD in genetically predisposed patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.17235/reed.2022.9152/2022 | DOI Listing |
Publication Analysis
Top Keywords
multiple sclerosis
12
crohn's disease
8
trigger ibd
8
disease induced
4
induced ocrelizumab
4
ocrelizumab patient
4
patient multiple
4
sclerosis drug-induced
4
drug-induced inflammatory
4
inflammatory bowel
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!